Vladimir Volloch
Overview
Explore the profile of Vladimir Volloch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volloch V, Rits-Volloch S
Genes (Basel)
. 2025 Jan;
16(1.
PMID: 39858593
A notion of the continuous production of amyloid-β (Aβ) via the proteolysis of Aβ-protein-precursor (AβPP) in Alzheimer's disease (AD)-affected neurons constitutes both a cornerstone and an article of faith in...
2.
Volloch V, Rits-Volloch S
Int J Mol Sci
. 2024 Sep;
25(18).
PMID: 39337400
The present study analyzes two potential therapeutic approaches for Alzheimer's disease (AD). One is the suppression of the neuronal integrated stress response (ISR). Another is the targeted degradation of intraneuronal...
3.
Volloch V, Rits-Volloch S
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892224
The centrality of amyloid-beta (Aβ) is an indisputable tenet of Alzheimer's disease (AD). It was initially indicated by the detection (1991) of a mutation within Aβ protein precursor (AβPP) segregating...
4.
Volloch V, Rits-Volloch S
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38474228
For at least two reasons, the current transgenic animal models of Alzheimer's disease (AD) appear to be patently inadequate. They may be useful in many respects, the AD models; however,...
5.
Volloch V, Rits-Volloch S
Int J Mol Sci
. 2023 Dec;
24(24).
PMID: 38139415
Although the long-standing Amyloid Cascade Hypothesis (ACH) has been largely discredited, its main attribute, the centrality of amyloid-beta (Aβ) in Alzheimer's disease (AD), remains the cornerstone of any potential interpretation...
6.
Volloch V, Rits-Volloch S
J Alzheimers Dis Rep
. 2023 Oct;
7(1):921-955.
PMID: 37849639
With the Amyloid Cascade Hypothesis (ACH) largely discredited, the ACH2.0 theory of Alzheimer's disease (AD) has been recently introduced. Within the framework of the ACH2.0, AD is triggered by amyloid-β...
7.
Volloch V, Rits-Volloch S
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569624
With the long-standing amyloid cascade hypothesis (ACH) largely discredited, there is an acute need for a new all-encompassing interpretation of Alzheimer's disease (AD). Whereas such a recently proposed theory of...
8.
Volloch V, Rits-Volloch S
J Alzheimers Dis
. 2023 May;
93(4):1277-1284.
PMID: 37212119
In clinical trials, lecanemab and donanemab showed statistically significant yet marginal slowdown of Alzheimer's disease (AD)-associated cognitive decline. This could be due to their sub-optimal design and/or deployment; alternatively, their...
9.
Volloch V, Rits-Volloch S
J Alzheimers Dis Rep
. 2023 Feb;
7(1):21-35.
PMID: 36777328
Recently, we proposed the Amyloid Cascade Hypothesis 2.0 (ACH2.0), a reformulation of the ACH. In the former, in contrast to the latter, Alzheimer's disease (AD) is driven by amyloid-β (Aβ)...
10.
Volloch V, Rits-Volloch S
J Alzheimers Dis Rep
. 2022 Sep;
6(1):369-399.
PMID: 36072366
We posit that Alzheimer's disease (AD) is driven by amyloid-β (Aβ) generated in the amyloid-β protein precursor (AβPP) independent pathway activated by AβPP-derived Aβ accumulated intraneuronally in a life-long process....